Article: Forecasting company predicts anticholesterol market share for Vytorin.

2004 AUG 30 - (NewsRx.com & NewsRx.net) -- Princeton Brand Econometrics (PBE) forecasts a maximum potential 11.7% share of the anticholesterol market for Vytorin, a joint-venture product of Schering-Plough Corporation (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) that was approved last month by the U.S. Food and Drug Administration.

Vytorin combines two anticholesterol agents, Zocor, sold by Merck, and Zetia, jointly sold by both companies. Merck/Schering-Plough Pharmaceuticals claims that the new combination results in dramatic decreases in LDL (bad cholesterol) without meaningful increases in side effects. The lowest dose of Vytorin has been found to be more ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!